Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander G G Turpie

Showing results (81-90 of 177) with videos related to

Pageof 18
Sort By:
Thrombosis and Haemostasis|October 2, 2010
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgeryJeffrey I Weitz, Charlie Cao, Bengt I Eriksson, et al.
European Heart Journal|September 3, 2015
XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillationA John Camm, Pierre Amarenco, Sylvia Haas, et al.
Journal of the American Heart Association|February 22, 2020
Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With RivaroxabanPaulus Kirchhof, Sylvia Haas, Pierre Amarenco, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|July 2, 2019
Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTEWalter Ageno, Lorenzo G Mantovani, Sylvia Haas, et al.
Current Medical Research and Opinion|July 6, 2017
A post-marketing assessment of major bleeding in total hip and total knee replacement surgery patients receiving rivaroxabanLouis M Kwong, Alexander G G Turpie, Sally Tamayo, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|June 29, 2019
Patient Management Strategies and Long-Term Outcomes in Isolated Distal Deep-Vein Thrombosis versus Proximal Deep-Vein Thrombosis: Findings from XALIAWalter Ageno, Lorenzo G Mantovani, Sylvia Haas, et al.
Clinical Cardiology|July 1, 2016
Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS-ACTS SubstudyCraig I Coleman, Sylvia Haas, Alexander G G Turpie, et al.
The New England Journal of Medicine|June 27, 2008
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplastyMichael R Lassen, Walter Ageno, Lars C Borris, et al.
Thrombosis Research|March 7, 2006
Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in CanadaSusan R Kahn, Akbar Panju, William Geerts, et al.
Thrombosis and Haemostasis|January 10, 2009
A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)Alexander G G Turpie, Kenneth A Bauer, Bruce L Davidson, et al.
Pageof 18

Showing results (81-90 of 177) with videos related to

Sort By:
Pageof 18
Thrombosis and Haemostasis|October 2, 2010
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgeryJeffrey I Weitz, Charlie Cao, Bengt I Eriksson, et al.
European Heart Journal|September 3, 2015
XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillationA John Camm, Pierre Amarenco, Sylvia Haas, et al.
Journal of the American Heart Association|February 22, 2020
Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With RivaroxabanPaulus Kirchhof, Sylvia Haas, Pierre Amarenco, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|July 2, 2019
Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTEWalter Ageno, Lorenzo G Mantovani, Sylvia Haas, et al.
Current Medical Research and Opinion|July 6, 2017
A post-marketing assessment of major bleeding in total hip and total knee replacement surgery patients receiving rivaroxabanLouis M Kwong, Alexander G G Turpie, Sally Tamayo, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|June 29, 2019
Patient Management Strategies and Long-Term Outcomes in Isolated Distal Deep-Vein Thrombosis versus Proximal Deep-Vein Thrombosis: Findings from XALIAWalter Ageno, Lorenzo G Mantovani, Sylvia Haas, et al.
Clinical Cardiology|July 1, 2016
Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS-ACTS SubstudyCraig I Coleman, Sylvia Haas, Alexander G G Turpie, et al.
The New England Journal of Medicine|June 27, 2008
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplastyMichael R Lassen, Walter Ageno, Lars C Borris, et al.
Thrombosis Research|March 7, 2006
Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in CanadaSusan R Kahn, Akbar Panju, William Geerts, et al.
Thrombosis and Haemostasis|January 10, 2009
A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)Alexander G G Turpie, Kenneth A Bauer, Bruce L Davidson, et al.
Pageof 18